Investigateur principal pour des études cliniques

  Jan 2024 : Investigateur principal, coordonateur national : “A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)” (NCT04772235)

 Juin 2023 : investigateur principal “A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY” (Astra Zeneca) NCT05450692

 Avril 2023 : Investigateur principal “A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer” (ABBVie M18-868 TELIMET) NCT04928846

 Octobre 2022 : investigateur principal “A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non-small cell lung cancer” (IFCT 2101) (NCT05200481)

 Septembre 2022 : investigateur principal “An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non�'Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations” (Gilead) (NCT05186974)

 Mars 2022 : investigateur principal “A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic NonSmall Cell Lung Cancer After Osimertinib Failure (MARIPOSA2)” (NCT04988295)

 Février 2022 : investigateur principal “A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreaK 201) ” (NCT04933695)

Janvier 2022 : investigateur principal : “A randomized, open-label, controlled phase III trial comparing the pembrolizumab-platinum-based chemotherapy combination with pembrolizumab monotherapy in first-line treatment of non-small-cell lung cancer (NSCLC) patients with PD-L1 expression ≥50% on tumor cells PERSEE trial-GFPC 01-2020” (NCT NCT04547504)

 Décembre 2021 : investigateur principal : “A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-Line Treatment (CodeBreaK 201) (NCT NCT04933695)

 Septembre 2021 : Investigateur principal : “Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)” (NCT NCT04642469)

 Février 2021 Investigateur principal : “a randomized, phase 2, double-blind study to evaluate the efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung cancer” (GSK PERLA) (NCT04581824)

  Janvier 2021 : Investigateur principal : “MARIPOSA : A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer” (Protocol 73841937NSC3003 - NCT : NCT04487080)

 Octobre 2020 : Coordonateur national et investigateur principal : “Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non-small-cell lung cancer (NSQ NSCLC)” (ACT16146 - NCT :  NCT04524689)

 Janvier 2020 : Investigateur principal : «A multicenter phase II, open-label, non-randomized study evaluating Platinum Pemetrexed-Atezolizumab (+/- Bevacizumab) for patients with stage IIIB/IV non squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies » (IMMUNO-ADDICT ; GFPC 06-2018) (NCT04042558)

 Janvier 2020 : Investigateur principal : « A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy. » (Merck MS200095-0031) (NCT03940703)

 Octobre 2019 : investigateur principal : « A phase Ib/II, Open label study of M7824 in combination with chemotherapy in Participants with stage IV Non Small Cell Lung Cancer » (Merck MS200647-0024) (NCT03840915)

 Juin 2019 : investigateur principal : « A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib » (ALTA-2) (NCT03535740)

 Mars 2019 : Coordonateur national et investigateur principal : « A Phase 3 Randomized Open-label Study of Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib» (Brigatinib-3001) (NCT03596866)

 Décembre 2018 : Coordonateur national et investigateur principal : « A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer » (Merck MS200647-0037) (NCT03631706)

 Juin 2018 : Investigateur principal de l'étude de phase III : «A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)» (Novartis  CACZ885T2301) (NCT03447769)

 Novembre 2017 : Investigateur principal de l'étude de phase III : «A phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first-line treatment of patients with advanced alk-positive non-small cell lung cancer » (Pfizer B7461006) (NCT03052608)

 Septembre 2017 : Investigateur principal de l'étude de phase III : « A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU) » (Abbvie M16-298) (NCT03033511)

 Juillet 2017 : Investigateur principal de l'étude de phase III : « A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy» (Abbvie M16-289) (NCT03061812)

 Juin 2017 : Coordonateur international étude de roll-over : « A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer » (Roche BO39694) (NCT03194893)

 Juin 2017 : Investigateur principal de l'étude de phase II : « an open-label, multicenter, single arm, phase II study to assess the efficacy and safety of alectinib in patients with alk-rearranged non�'small cell lung cancer after disease progression on prior alk inhibitor therapy» (Etude ROCHE ML39349) (NCT03155009)

 Aout 2016 : Coordonateur national, Investigateur principal de l'étude de phase II : « A Phase II single-arm trial to investigate tepotinib in stage IIIB/IV adenocarcinoma of the lung with MET exon 14 (METex14) skipping alterations after failure of at least one prior active therapy, including a platinum-doublet-containing regimen » (Etude Merck MS200095-0022) (NCT02864992)

 Juin 2016 : Investigateur principal de l'étude de phase III : « An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations » (etude SOLAR 225212) (NCT02588261)

 Mars 2016 : Investigateur principal de l'étude de phase III : « A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer » (Etude EMR100070-005) (NCT02576574)

 Février 2016 : Investigateur principal de l'étude de phase III : “Randomized, multicenter, phase II, open label study of Alectinib versus Pemetrexed or Docetaxel in ALK positive advanced non small cell lung cancer patients previously treated with platinum-based chemotherapy and Crizotinib” (étude MO29750) (NCT02604342)

 Janvier 2016 : Investigateur principal de l'étude de phase III : “An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with  hemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)” (étude CHECKMATE 227 : CA209227) (NCT02477826)

 Octobre 2015 : Investigateur principal de l'étude de phase III : « A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer » (Etude GO29436) (NCT02366143)

 Septembre 2015 :  Investigateur principal de l'étude de phase III : « A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet » (etude EMR100070-004 ) (NCT02395172)

 Avril 2015 : Investigateur principal de l'étude de phase III : « ALEX Study : A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants » (etude BO28984) (NCT02075840)

 Mars 2015 : Investigateur principal de l'étude de phase I : « Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer » (etude D5160C00019) (NCT02317016)

 Février 2015 : Investigateur principal de l'étude de phase III : « A Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) » (etude M11-089) (NCT02106546)

 Novembre 2014 : Investigateur principal de l'étude de phase II : « A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC) » (etude D4191C00003 ) (NCT02087423)

 Octobre 2014 : Investigateur principal de l'étude de phase II : « A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) » (etude C14018) (NCT02038647)

 Avril 2014 : Investigateur principal sur le CHU de Bordeaux de la cohorte poumon du programme ACSé Crizotinib (promoteur : Unicancer)

Février 2014 : Investigateur principal de l'étude de phase II : « A Randomized, Multi-Center Phase 2 Trial of Denosumab in Combination with Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung Cancer  » (etude 20120249) (NCT01951586)

 Septembre 2013 : Investigateur principal de l'étude de phase I/II Accalia : « An open-label, non-randomized, multicenter phase I/II trial of RO5424802 given orally to non'small cell lung cancer patients who have ALK mutation and failed crizotinib treatment » (étude NP26873) (NCT01801111)

Rédacteur et contributeurs de publications

 Ladouceur, Alexandra, Thomas Barnetche, Gael Mouterde, Alice Tison, Samuel Bitoun, Sorilla Prey, Caroline Dutriaux, et al. « Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicentre Observational Study ». RMD Open 9, n^o 4 (29 novembre 2023): e003795. https://doi.org/10.1136/rmdopen-2023-003795.

2.     Le, Xiuning, Luis G. Paz-Ares, Jan Van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez, Egbert F. Smit, Marina Garassino, et al. « Tepotinib in Patients with Non-Small Cell Lung Cancer with High-Level MET Amplification Detected by Liquid Biopsy: VISION Cohort B ». Cell Reports. Medicine 4, n^o 11 (21 novembre 2023): 101280. https://doi.org/10.1016/j.xcrm.2023.101280.

3.     Decroisette, Chantal, Laurent Greillier, Hubert Curcio, Maurice Pérol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, et al. « Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study) ». Journal of Immunotherapy (Hagerstown, Md.: 1997), 9 octobre 2023. https://doi.org/10.1097/CJI.0000000000000490.

4.     Cho, Byoung Chul, Jong Seok Lee, Yi-Long Wu, Irfan Cicin, Manuel Cobo Dols, Myung-Ju Ahn, Kristof Cuppens, et al. « Bintrafusp Alfa versus Pembrolizumab in Patients with Treatment-Naive, PD-L1-High Advanced Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 3 Trial ». Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 17 août 2023, S1556-0864(23)00738-4. https://doi.org/10.1016/j.jtho.2023.08.018.

5.     Babey, Hélène, Philippe Jamme, Hubert Curcio, Jean Baptiste Assié, Remi Veillon, Hélène Doubre, Maurice Pérol, et al. « Real-World Treatment Outcomes of MET Exon14 Skipping in Non-Small Cell Lung Cancer: GFPC 03-18 Study ». Targeted Oncology, 13 juin 2023. https://doi.org/10.1007/s11523-023-00976-4.

6.     Mazieres, Julien, Paul K. Paik, Marina C. Garassino, Xiuning Le, Hiroshi Sakai, Remi Veillon, Egbert F. Smit, et al. « Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-Term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial ». JAMA Oncology, 4 juin 2023, e231962. https://doi.org/10.1001/jamaoncol.2023.1962.

7.     Pons-Tostivint, E., P. Hulo, V. Guardiolle, L. Bodot, A. Rabeau, M. Porte, S. Hiret, et al. « Real-World Multicentre Cohort of First-Line Pembrolizumab Alone or in Combination with Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer PD-L1 ≥ 50 ». Cancer Immunology, Immunotherapy: CII 72, n^o 6 (juin 2023): 1881‑90. https://doi.org/10.1007/s00262-022-03359-2.

8.     Descourt, Renaud, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Radj Gervais, et al. « First-Line Single-Agent Pembrolizumab for PD-L1-Positive (Tumor Proportion Score ≥ 50%) Advanced Non-Small Cell Lung Cancer in the Real World: Impact in Brain Metastasis: A National French Multicentric Cohort (ESCKEYP GFPC Study) ». Cancer Immunology, Immunotherapy: CII 72, n^o 1 (janvier 2023): 91‑99. https://doi.org/10.1007/s00262-022-03232-2.

9.     Guisier, Florian, Renaud Descourt, Helene Babey, Eric Huchot, Lionel Falchero, Remi Veillon, Alexis B. Cortot, Claire Tissot, Christos Chouaid, et Chantal Decroisette. « Brief Report: First-Line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study) ». Clinical Lung Cancer 23, n^o 8 (décembre 2022): e545‑49. https://doi.org/10.1016/j.cllc.2022.09.002.

10.  Rosellini, Pietro, Samuel Amintas, Charline Caumont, Rémi Veillon, Sigolène Galland-Girodet, Alain Cuguillière, Laurent Nguyen, et al. « Clinical Impact of STK11 Mutation in Advanced-Stage Non-Small Cell Lung Cancer ». European Journal of Cancer (Oxford, England: 1990) 172 (septembre 2022): 85‑95. https://doi.org/10.1016/j.ejca.2022.05.026.

11.  Toublanc, Anne-Claire, Marina Guecamburu, Rémi Veillon, Pietro Rosellini, Pierre-Olivier Girodet, et Maeva Zysman. « Second-Line Lurbinectedin as a New Treatment Option for Small-Cell Lung Cancer: Preliminary Results in Real-Clinical Practice ». Thoracic Cancer 13, n^o 15 (août 2022): 2248‑52. https://doi.org/10.1111/1759-7714.14464.

12.  Veillon, Remi, Hiroshi Sakai, Xiuning Le, Enriqueta Felip, Alexis B. Cortot, Egbert F. Smit, Keunchil Park, et al. « Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management ». Clinical Lung Cancer 23, n^o 4 (juin 2022): 320‑32. https://doi.org/10.1016/j.cllc.2022.03.002.

13.  Heraudet, Luc, Tara Delon, Rémi Veillon, Charlotte Vergnenègre, Hélène Lepetit, Amaury Daste, Alain Ravaud, Maéva Zysman, et Charlotte Domblides. « Effect of Prior Immunotherapy on the Efficacy of Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Retrospective Study ». Thoracic Cancer 13, n^o 9 (mai 2022): 1391‑1400. https://doi.org/10.1111/1759-7714.14403.

14.  Gefard-Gontier, E., R. Markich, M. Zysman, R. Veillon, A. Daste, C. Domblides, B. Sionneau, et al. « Evolution of Bone Metastases in Patients Receiving at Least Three Months of Checkpoint Inhibitors ». Cancer Immunology, Immunotherapy: CII, 19 mars 2022. https://doi.org/10.1007/s00262-022-03180-x.

15.  Faubry, Clara, Maxime Faure, Anne-Claire Toublanc, Rémi Veillon, Anne-Iris Lemaître, Charlotte Vergnenègre, Hubert Cochet, et al. « A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer ». Frontiers in Cardiovascular Medicine 9 (2022): 878211. https://doi.org/10.3389/fcvm.2022.878211.

16.  Haik, Laura, Aurore Gonthier, Amandine Quivy, Marine Gross-Goupil, Remi Veillon, Eric Frison, Alain Ravaud, Charlotte Domblides, et Amaury Daste. « The Impact of Sarcopenia on the Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Solid Tumours ». Acta Oncologica (Stockholm, Sweden) 60, n^o 12 (décembre 2021): 1597‑1603. https://doi.org/10.1080/0284186X.2021.1978540.

17.  Kostine, Marie, Eleonora Mauric, Alice Tison, Thomas Barnetche, Aurélien Barre, Macha Nikolski, Léa Rouxel, et al. « Baseline Co-Medications May Alter the Anti-Tumoural Effect of Checkpoint Inhibitors as Well as the Risk of Immune-Related Adverse Events ». European Journal of Cancer (Oxford, England: 1990) 157 (novembre 2021): 474‑84. https://doi.org/10.1016/j.ejca.2021.08.036.

18.  Paik, Paul K., Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina C. Garassino, Julien Mazieres, et al. « Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations ». The New England Journal of Medicine 383, n^o 10 (3 septembre 2020): 931‑43. https://doi.org/10.1056/NEJMoa2004407.

19.  Gobbini, Elisa, Anne Claire Toffart, Maurice Pérol, Jean-Baptiste Assié, Michaël Duruisseaux, Dahna Coupez, Catherine Dubos, et al. « Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients ». Clinical Lung Cancer 21, n^o 5 (septembre 2020): e497‑510. https://doi.org/10.1016/j.cllc.2020.04.013.

20.  Dusselier, Matthieu, Elise Deluche, Nellie Delacourt, Julia Ballouhey, Thomas Egenod, Boris Melloni, Charlotte Vergnenègre, Rémi Veillon, et Alain Vergnenègre. « Neutrophil-to-Lymphocyte Ratio Evolution Is an Independent Predictor of Early Progression of Second-Line Nivolumab-Treated Patients with Advanced Non-Small-Cell Lung Cancers ». PloS One 14, n^o 7 (2019): e0219060. https://doi.org/10.1371/journal.pone.0219060.

21.  Tison, Alice, Gilles Quéré, Laurent Misery, Elisa Funck-Brentano, François-Xavier Danlos, Emilie Routier, Caroline Robert, et al. “Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.” Arthritis & Rheumatology (Hoboken, N.J.) 71, no. 12 (December 2019): 2100-2111. https://doi.org/10.1002/art.41068.

22.  Couraud, Sébastien, Fabrice Barlesi, Clara Fontaine-Deraluelle, Didier Debieuvre, Jean-Philippe Merlio, Lionel Moreau, Michèle Beau-Faller, et al. “Clinical Outcomes of Non-Small-Cell Lung Cancer Patients with BRAF Mutations: Results from the French Cooperative Thoracic Intergroup Biomarkers France Study.” European Journal of Cancer (Oxford, England: 1990) 116 (July 2019): 86-97. https://doi.org/10.1016/j.ejca.2019.04.016.

23.  Mazières, J., A. Drilon, A. Lusque, L. Mhanna, A. B. Cortot, L. Mezquita, A. A. Thai, et al. “Immune Checkpoint Inhibitors for Patients with Advanced Lung Cancer and Oncogenic Driver Alterations: Results from the IMMUNOTARGET Registry.” Annals of Oncology: Official Journal of the European Society for Medical Oncology, May 24, 2019. https://doi.org/10.1093/annonc/mdz167.

24.  Laurent, Elodie, Hugues Begueret, Benjamin Bonhomme, Rémi Veillon, Matthieu Thumerel, Valérie Velasco, Véronique Brouste, et al. “SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-Negative Breast Cancer and TTF1-Negative Lung Adenocarcinoma.” The American Journal of Surgical Pathology 43, no. 3 (March 2019): 293-302. https://doi.org/10.1097/PAS.0000000000001216.

25.  Ferrara, Roberto, Laura Mezquita, Matthieu Texier, Jihene Lahmar, Clarisse Audigier-Valette, Laurent Tessonnier, Julien Mazieres, et al. “Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.” JAMA Oncology, September 6, 2018. https://doi.org/10.1001/jamaoncol.2018.3676.

26.  Kostine, Marie, Léa Rouxel, Thomas Barnetche, Rémi Veillon, Florent Martin, Caroline Dutriaux, Léa Dousset, et al. “Rheumatic Disorders Associated with Immune Checkpoint Inhibitors in Patients with Cancer-Clinical Aspects and Relationship with Tumour Response: A Single-Centre Prospective Cohort Study.” Annals of the Rheumatic Diseases 77, no. 3 (March 2018): 393-98. 

doi : 10.1136/annrheumdis-2017-212257

27.  Domblides, C., L. Masse, and R. Veillon. “Les méningites carcinomateuses dans le cancer du poumon.” Revue des Maladies Respiratoires Actualités 9, no. 2 (September 2017): 288-98. https://doi.org/10.1016/S1877-1203(17)30060-5.

28.  Duruisseaux, Michaël, Benjamin Besse, Jacques Cadranel, Maurice Pérol, Bertrand Mennecier, Laurence Bigay-Game, Renaud Descourt, et al. “Overall Survival with Crizotinib and next-Generation ALK Inhibitors in ALK-Positive Non-Small-Cell Lung Cancer (IFCT-1302 CLINALK): A French Nationwide Cohort Retrospective Study.” Oncotarget 8, no. 13 (March 28, 2017): 21903-17. doi:10.18632/oncotarget.15746.

Barlesi, Fabrice, Julien Mazieres, Jean-Philippe Merlio, Didier Debieuvre, Jean Mosser, Hervé Lena, L'Houcine Ouafik, et al. “Routine Molecular Profiling of Patients with Advanced Non-Small-Cell Lung Cancer: Results of a 1-Year Nationwide Programme of the French Cooperative Thoracic Intergroup (IFCT).”Lancet (London, England) 387, no. 10026 (April 2, 2016): 1415-26. doi:10.1016/S0140-6736(16)00004-0

Caumont, Charline, Rémi Veillon, Audrey Gros, Elodie Laharanne, Hugues Bégueret, and Jean-Philippe Merlio. “Neuroendocrine Phenotype as an Acquired Resistance Mechanism in ALK-Rearranged Lung Adenocarcinoma.” Lung Cancer 92 (February 2016): 15-18. doi:10.1016/j.lungcan.2015.12.001.

Veillon, R., et Julien Mazieres. « Indication et utilisation des inhibiteurs de Tyrosine kinase dans la cancer bronchique non à petites cellules ». la lettre du pharmacologue 3 (novembre 2012).

Veillon, Rémi, Julien Mazieres, et Laurent Greillier. « Actualités concernant les thérapies ciblées en oncologie thoracique en 2011 ». la lettre du pneumologue XIV, n^o. 6 (décembre 2011)

Veillon, R., et J. Mazières. « Résultats des stratégies ciblées des cancers bronchiques non à petites cellules en 2011 ». Revue des Maladies Respiratoires Actualités 3, n^o. 4 (septembre 2011): 423-427.